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As we entered the decade of the 1980s. liver transplan-tation was not a therapeutic option considered for 
many patients with end stage liver disease. Although 
limited success had been achieved in a few centers with 
immunosuppression based on azathioprine. steroids. and 
polyclonal antibody preparations. patient survival rates 
were approximately PR~ at I year and less than ~ at 5 
years. 
By the end of the decade a remarkable change had taken 
place. and transplantation is now the therapeutic option of 
choice for many patients with irreversible end stage liver 
disease. We here review our experience over most of the 
last decade with liver transplantation under cyclosporine· 
prednisone induction and maintenance therpy at the 
University of Pittsburgh. 
MATERIALS AND METHODS 
The liver transplantation program at the University of Pittsburgh 
began in 1981. In the year.; from 1981 to 1989. 2.395 li .. er grafts 
were transplanted after total hepatectomy into 1.819 recipients in 
the conventional onhotopic approach (Fig I). Of these. ~:!9 grafts 
in 1583 patients were performed using cyclosporine-prednisone 
induction and maintenance therapy. Since 1984 we have used 
OKT3 (Orthoclone OKT-38 • Onho Pharmaceuticals. Raritan. NJ, 
for treatment of steroid-resistant rejection. 
A computer registry has been maintained since 1983 to track 
outcome in all graft reci~nts and the records for the complete 
series of 1.583 patients ~ere reviewed. I Variables included in the 
analysis are age at the time of transplantation. ABO blood group. 
body weight. primary her disease. graft survi,,·a1. and patient 
survival. In addition. since October 1987. patients have been 
classified for medical urgency according to the required level of 
medical care. 
Descriptive statistics were determined using SPSS/PC + version 
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fig 1. Primary liver tnnplantations per calendar year at the 
University of Pittsburgh between 1981 and 1989 induding 1583 
patients done under cydosporine-prednisone ~K 147 pa-
tients whose grafts were rescued by conversion to FK 506. and 89 
patients treated with primary induction and maintenance with FK 
506. 
3.1 (SPSS Inc .. Chicago. III) and survival analysis was performed 
using BMDP/PC (1988 version. BMDP Statistical Soft'A'are. Los 
Angeles. CaliO on an Intel 80386 based microcomputer running 
MS-OOS 4.01 (Microsoft Corporation. Bellevue. Wash). 
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fig 2. Primary transplantations per calendar year according to 
(A) sex, (8) age group. and (e) primary liver disease. See Table 1 
10f' definition of age groups. 
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Table 1. Pen:enI PatIent Survival According to Age and Weight at Time of Transplantation" 
Aqe E~rsF 1\1 , month 6 :!7IOnI'a 1 year 2 years 3 years 4 years R~ 
Infant under 2 135 81.5 66.7 
Child 2to 11 2fi7 87.3 76..0 
Adolescent 12 to 17 5E 82.1 7'.4 
Adult 18 to 59 998 89.7 76.3 
Senior over 60 127 86.6 71.7 
Under 7 kg 5E 78.6 6&.3 
7tol1kg 129 83.0 65. I 
121019kg 149 89.3 n.9 
20 to 39 kg S- 89.4 83..0 
40 kg or more 973 90.0 n5 
-Life table method. 
RESULTS 
As shown in Fig I. there has been a ~gnificant increase in 
the number of new patients receiving transplants through 
1988. In 1989. we began converting te an immunosuppres-
sive protocol based on the new dr'Jg FK 506. so the 
number of patients in the cyclosporine (Cy A) based group 
began to decline for the first time. 
Sex 
There were 769 (48.6%) males and 81-4 (51.4%) females in 
this series. There has been an increas.c in the proportion of 
males in the series in the last 2 yean 154.9% in 1988 and 
54.59C in 1989. Fig 2A). This probably reflects a decrease in 
the proportion of transplantations performed at this center 
for cholestatic liver disease. especiall:- for primary biliaT) 
cirrhosis. which has a high prevalence In females (Fig 20. 
Age Groups 
There were 135 (8.5%) infants (age l,;nder 2 years). 26-;" 
(l6.Wc) children (age 2 to II years). 56 13.5%) adolescents 
(age 12 to 17 years). 998 (63.0%) adults • age 18 to 59 years). 
and 127 (8.0%) senior (over 60 years) recipients. The 
proportion of infants in the series has remained between 
89C to 10% since 1985 (Fig 2B). Most ~gnificant has been 
the increase in the number and proportion of senior 
patients accepted in the program from 3.6% in 1985 to 
14.79C in 1989 (Fig 2B). 
Body weight is related to age but may be a better 
measure of developmental status in children. Fifty-six 
(3.59C) of the recipients weighed less than 7 kg and 129 
(8.19C) weighed 7 to II kg. 
Survival rates based on age group and body weight are 
63.6 61.7 60 .• 58.3 RRK~ 
73.8 71.4 70.5 68.8 68.-
69.6 63.6 63.6 60.6 60e 
73.7 69.0 66.4 64.2 62.8 
69.3 66.0 61.9 61.9 
56.9 52.2 48.6 48.6 41 e 
64.3 63.4 62.3 60.8 60.5 
74.5 71.6 71.6 68.8 67"7' 
81.9 SO.8 78.0 76.1 TSK~ 
75.0 70.6 68.3 65.9 63! 
shown in Table I. Survival rates for infants are 69<: to f~ 
lower at I year and 5% to 8% lower at 5 years than fOf" 
other age groups. Pediatric recipients under 12 kg bod\ 
weight have a 109C to 20% higher mortality than larg'; 
patients. 
Blood Groups 
Patient survival based on recipient ABO blood groups are 
summarized in Table 2. We have not observed a difference 
in survival based solely on recipient blood group. 
Primary liver Disease 
The most common indication for liver replacement in this 
series is post necrotic cirrhosis (432 patients. 27.39<:1 fol-
lowed by cholestatic liver disease including primary biliary 
cirrhosis and primary sclerosing cholangitis 1324, 20.5%). 
biliary atresia (265. 16.7%). alcoholic cirrhosis (134. 8.59<: l. 
inborn errors of metabolism 032. 8.3%). primary hepato-
biliary cancer (105. 6.6%). and fulminant hepatic failure 
175. 4.7%). 
Patient survival based on primary liver disease is sum-
marized in Table 3. The highest patient survival rates are 
seen in patients receiving liver grafts for inborn errors of 
metabolism. cholestatic liver disorders. postnecrotic cir-
rhosis (excluding HBsAg+ patients). and alcoholic cirrho-
sis. 
Since 1985 there has been a significant increase in the 
proportion of patients receiving liver grafts at this center 
for alcoholic cirrhosis (from 3.0% in 1985 to 15.6% in 1989. 
Fig IC). Patient follow-up is maintained by a skilled team 
of nurse clinicians who keep up regular contact with 
patients. their families. and community physicians. We 
recently surveyed 121 surviving patients who received 
Table 2. PeranI Patient Survival a-d on Recipient ABO Blood Group" 
N , month 15 months 1~ 2 years 3 years .. years 5 years 
0 696.0 76.0 7".0 72.5 69.1 66.3 64.5 62.9 
A 625.0 87.8 74.2 72.5 68.3 67.0 65.9 64.6 
S 196.0 87.2 74.0 72.4 67.5 66.6 61.7 61.7 
AS 66.0 87.9 71.2 69.6 63.9 58.6 55.0 55.0 
'liIe !able method. 
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Table 3. Percent Patient Survlvel Based on Primary liver 01 ..... • 
N 1 monlh 6 months 
C/1C)Iestatic disorders 324 92.9 eo.3 
fIoStr1eCI'otic cirrhosis T 359 88.0 77.4 
AJcd10Iic cirrhosis 134 90.3 82.1 
Bia'Y atresia 265 84.2 71.7 
Neonatal hepatitis 7 85.7 71.4 
MetabOlic disorders 132 88.6 75.8 
Fumnanl failure 75 78.7 61.3 
C/ln)nic hepatitis B 73 86.3 63.0 
Pri'naI)' cancer 105 94.3 72.4 
Autoimmune hepatitis 42 85.7 83.3 
Budd-Chiari syndrome 24 79.2 66.7 
Sec;ondaty biliary cirrhosis 25 68.0 56.0 
1JIe Table method. 
'&ducing HBsAg+. 
grafts for alcoholic cirrhosis or for liver disease in which 
alcoholism was believed to be a significant contributing 
factor. Only 10 patients (S.3t;f) were known for certain to 
be actively drinking and 6 (5.0%) more patients were 
suspected to have resumed drinking. Thus. 105 patients 
(86.8t;f) were believed to be abstinent. This is consistent 
with the high survival rates seen after transplantation for 
alcoholic cirrhosis (80.6% at I year with 109 patients at risk 
and 75.1% at 2 years with 44 patients at risk). 
Lower survival rates are seen in patients receiving grafts 
for fulminant hepatic failure. chronic hepatitis B. and 
primary cancer. An interesting exception is the high sur-
vival for the 15 patients who received transplants for 
fulminant hepatitis B (8Ot;f survival at I year and at 5 
years. Table 4). 
Medical Urgency 
We recently summarized the experience in this center 
since the adoption of a national system for liver allocation 
in the United States. which places a heavy emphasis on 
medical urgency as measured by the level of medical 
support required by the patient waiting for a transplant. 2 
Fig 3 presents a life table survival plot adapted from this 
report for 812 patients who received grafts under the 
UNOS point system between October 1987 and December 
1989. There is a strong relationship (P < .(01) between 
medical condition of the patient classified in this manner 
and mortality after transplantation. 
Retransplantation 
Hepatic retransplantation in this series of patients will be 
the subject of a future report. In brief. of the 1583 patients 
1 year 2 years 3 years 4 years 5 yeatS 
77.8 75.7 74.3 72.2 71.1 
76.0 73.0 70.7 69.6 67.4 
eo.6 75.1 72.7 72.7 
69.4 67.6 66.6 63.8 62.8 
71.4 51.0 51.0 51.0 51.0 
75.0 75.0 75.0 73.8 73.8 
60.0 53.8 49.0 49,0 49.0 
58.8 48.6 48,6 48.6 48.6 
63.7 43.7 33.0 26.4 26.4 
83.3 eo.4 eo.4 eo.4 
66.7 66.7 54.6 54.6 54.6 
51.9 51.9 51.9 51.9 51.9 
in this series. as of June 30. 1990. 1216 received only one 
graft and 367 (24.0£it) had required at least one retransplan-
tation. The primary nonfunction rate for the series of first 
grafts is 6.69C. The highest incidence of retransplantation is 
in patients who received their first graft for biliary atresia 
/28.0%) or for fulminant hepatic failure (27.5%). Lowest 
retransplantation rates are in patients receiving transplants 
for alcoholic cirrhosis (13.5%) and primary biliary cirrhosis 
(18.4%). 
DISCUSSION 
The experience reported here from this single large center 
and the accumulating experience in the multicenter regis-
tries reported elsewhere in these proceedings.3 demon-
strate the efficacy of liver transplantation for many forms 
of end stage liver disease. By 1985. it seemed evident from 
the first years of experience at this center with cyclospor-
ine-prednisone induction and maintenance therapy. that 
survival rates after liver transplantation approaching 759C 
to 80% at I year and 65t;f to 7Wc could be achieved for 
many patients.· These initial expectations are confirmed 
\Ioith this extended experience in nearly 1600 patients. 
Certainly. for postnecrotic cirrhosis (excluding HBV car-
riers). cholestatic liver disease. and inborn errors of me-
tabolism. these results have stood the test of time. 
High success rates have been achieved in the patients 
given a transplant for fulminant hepatitis B. as these 
patients develop antibodies and remain immune from 
reinfection. Although most of the HBsAg+ patients trans-
planted for post necrotic cirrhosis have remained virus 
carriers and many patients have developed detectable 
infection in the graft. there is still cause for optimism here. 
Teble 4. Pen:ant Patient Survlvel AfIIIr U"., Transpllntatlon for Acute or ChronIc Viral Hepmltls· 
N 1 month 6mon\hs 1 year 2 years 3 years 4 years 5 yellS 
Aorte non-A. non-B 32 84.4 68.8 68.8 58.7 SO.O SO.O SO.O 
CIvonic non-A. non-B 292 88.0 n.1 75.0 72.1 69.S 68.7 65.8 
Acute hepatitis B 15 86.7 eo.O eo.O 80.0 eo.O eo.O eo.O 
CIvonic hepatitis B 73 86.3 63.0 58.8 48.6 48.6 48.6 48.6 
1.Ie1able method. 
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Fig 3. Actuarial (life table) patient survival rates based on the 
level of medical care required by the recipient at the time of 
transplantation. 
too. Active and passive immunization and long-term ther-
apy with interferon may result in seroconversion of 
HBsAg+ patients and we believe that significant further 
improvement in patient survival can and will be 
achieved. 5.6 
Although survival after liver transplantation for infants 
and low body weight children is lower than for older or 
larger patients. improvement here is also beginning to be 
achieved. Improved methods of organ preservation with 
UW solution. which is believed to protect the microcircu-
lation of the liver. has reduced the incidence of arterial 
thrombotic complications and thus the need for retrans-
plantation. Increasing use of reduced liver grafts for small 
children increases the availability of organs for these 
patients and can help reduce the longer waiting times and 
consequent deterioration in their condition. Finally. rec-
ognition of the added technical difficulty that results from 
prior surgery on infants and small children needing liver 
transplantation should encourage discretion in the use of 
alternative. less-effective surgical procedures. 
Liver transplantation for alcoholic cirrhosis has been 
controversial. 7 Our initial experience with this group of 
patients led us to adopt an aggressive approach. and the 
number of patients with this disease treated at our center 
has been increasing yearly. The extended results reported 
here support continuation of this policy. 
GORDON. TODO. TZAKIS ET ~ 
Survival after liver transplantation is related to the 
patient's condition at the time of transplantation. We have 
been able to achieve nearty 90% I-year survival in patients 
who are able to be transplanted before they become 
dependent upon in-hospital care. compared to only 65% to 
70% survival in patients in the intensive care unit at the 
time of transplantation. This emphasizes the excellent 
results that can be achieved if patients have timely access 
to transplantation. Although efforts to ease the donor 
shortage must continue. it is equally important that pa-
tients who are potential candidates for liver replacement 
be referred to the transplant center before they have 
deteriorated to the point where the prospects for survival 
have significantly diminished. Liver transplantation is no 
longer an option to be taken out of desperation. 
We continue to experience high recurrence rates after 
liver transplantation for hepatobiliary cancer. Additional 
treatment ..... ith adjuvant chemotherapy or radiotherapy in 
the preoperative. intraoperative, and postoperative phases 
of care are being studied in a effort to improve results. 
As we enter the decade of the 1990s. new therapeutic 
agents such as FK 506. rapamycin, deoxyspergualin. and 
other agents may find widespread application in clinical 
transplantation. The results achieved during the last dec-
ade with cydosporine-prednisone therapy have provided a 
new standard against which results with these new agents 
will be compared. 
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